Medexus Pharmaceuticals Inc. (TSE:MDP - Free Report) - Investment analysts at Leede Financial dropped their FY2026 EPS estimates for shares of Medexus Pharmaceuticals in a report released on Friday, November 8th. Leede Financial analyst D. Loe now forecasts that the company will post earnings per share of $0.22 for the year, down from their previous estimate of $0.23. Leede Financial has a "Speculative Buy" rating and a $8.25 price objective on the stock. The consensus estimate for Medexus Pharmaceuticals' current full-year earnings is $0.16 per share. Leede Financial also issued estimates for Medexus Pharmaceuticals' FY2027 earnings at $0.60 EPS.
Several other research analysts have also recently weighed in on the stock. Stifel Canada upgraded shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a report on Monday, August 12th. Stifel Nicolaus upped their target price on shares of Medexus Pharmaceuticals from C$3.00 to C$3.50 and gave the stock a "buy" rating in a research note on Thursday, August 22nd.
Get Our Latest Stock Report on MDP
Medexus Pharmaceuticals Price Performance
MDP traded down C$0.14 during mid-day trading on Monday, hitting C$2.03. The stock had a trading volume of 54,161 shares, compared to its average volume of 41,036. The stock's fifty day simple moving average is C$2.55 and its 200-day simple moving average is C$2.18. The firm has a market capitalization of C$49.80 million, a price-to-earnings ratio of 40.60 and a beta of 1.96. Medexus Pharmaceuticals has a 1-year low of C$1.44 and a 1-year high of C$3.16.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
See Also
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a "Strong Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2025 and why they should be in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
